India Prepares for Launch of Generic Semaglutide Drugs Following Patent Expiry

India's semaglutide patent is set to expire in March 2026, enabling Indian pharmaceutical companies, including Dr Reddy's, Sun Pharma, Zydus Lifesciences, and Natco Pharma, to launch lower-cost generic versions of diabetes and weight-loss drugs like Ozempic and Wegovy. Dr Reddy's plans to introduce its generic semaglutide under the brand name Obeda, aiming to price it up to 60% lower than branded products. This development is expected to expand access and potentially grow the weight-loss drug market significantly in India.